Meridian Diagnostics LLC

Meridian Diagnostics LLC was paid $579K by Medicaid between Sep 2021 and Dec 2024, across 80 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 82% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Colorado

Rank by total paid#28 of 91

Median peer was paid$53K

This provider vs. median11×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	2,725	$19K
2022	8,124	$252K
2023	3,416	$192K
2024incomplete	1,425	$116K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	82%	3,964	3,530	$474K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.0%	57	54	$17K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.5%	526	485	$9K
87150		<1%	52	49	$5K
83970		<1%	264	258	$4K
82172		<1%	336	239	$4K
80061	Lipid panel	<1%	525	481	$4K
82607		<1%	426	398	$3K
84466		<1%	281	268	$3K
84481		<1%	393	366	$3K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	532	483	$3K
86141		<1%	217	212	$3K

68 more codes

84443	Thyroid stimulating hormone (TSH)	<1%	539	$3K
80053	Comprehensive metabolic panel	<1%	609	$3K
83036	Hemoglobin; glycosylated (A1C)	<1%	472	$2K
82670		<1%	190	$2K
83540		<1%	368	$2K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	19	$2K
84439		<1%	413	$2K
82746		<1%	262	$2K
83090		<1%	239	$2K
87481		<1%	45	$1K
87511		<1%	56	$1K
84550		<1%	467	$1K
82533		<1%	211	$1K
84403		<1%	86	$1K
83001		<1%	148	$1K
84146		<1%	145	$1K
86800		<1%	163	$1K
82728		<1%	81	$981.36
86376		<1%	163	$902.10
83002		<1%	95	$845.45
87640		<1%	57	$736.89
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	56	$736.89
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	44	$701.80
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	44	$701.80
87529		<1%	44	$701.80
82627		<1%	47	$666.90
82977		<1%	260	$648.00
83735		<1%	237	$623.10
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	270	$613.83
84270		<1%	48	$608.44
87641		<1%	52	$596.53
87500		<1%	52	$596.53
87563		<1%	39	$561.44
84153		<1%	30	$533.31
84165		<1%	55	$504.78
84432		<1%	48	$433.62
85027		<1%	88	$420.55
83550		<1%	123	$410.78
86200		<1%	47	$388.50
82330		<1%	48	$355.68
83721		<1%	47	$336.00
82553		<1%	47	$323.40
84450		<1%	93	$305.62
86140		<1%	87	$290.08
84075		<1%	64	$238.28
84460		<1%	65	$227.90
82040		<1%	64	$227.70
82247		<1%	65	$210.84
87653		<1%	15	$210.54
82565		<1%	77	$184.32
82435		<1%	64	$179.40
82310		<1%	65	$170.28
84155		<1%	77	$168.82
84295		<1%	65	$168.35
82374		<1%	48	$156.16
84520		<1%	64	$154.05
86593		<1%	49	$154.00
86431		<1%	48	$147.42
82947		<1%	65	$117.90
84830		<1%	17	$114.30
84154		<1%	13	$110.34
84436		<1%	84	$82.44
82248		<1%	34	$75.30
81003		<1%	28	$60.75
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	17	$35.92
84479		<1%	66	$12.94
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	0%	99	$0.00
G0307	Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count)	0%	130	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWALCOTT, RHYAN (CEO)